AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12914552 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 12914552 — intervention group
Group type: COMPARATOR
Intervention: Active standard control
Number of subjects: 0
Study 10986541 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for general practitioners' reception staff
Number of subjects: 26
Study 10986541 — intervention group
Group type: COMPARATOR
Intervention: Fixed effect (FE) summary statistic method
Number of subjects: 26
Study 10986541 — intervention group
Group type: COMPARATOR
Intervention: Ordinary logistic regression
Number of subjects: 26
Study 10986541 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal model based on generalized estimating equations
Number of subjects: 26
Study 10986541 — intervention group
Group type: COMPARATOR
Intervention: Random effects (RE) summary statistic method
Number of subjects: 26
Study 9190848 — intervention group
Group type: EXPERIMENTAL
Intervention: dynorphin A(1-13) 0.1 mg/kg, 0.32 mg/kg, 1 mg/kg (15-min i.v. infusion)
Number of subjects: 6
Study 9190848 — intervention group
Group type: COMPARATOR
Intervention: dynorphin A(1-13) 1 mg/kg (15-min i.v.) after morphine pretreatment
Number of subjects: 6
Study 9190848 — intervention group
Group type: COMPARATOR
Intervention: morphine pretreatment 45 mg/70 kg i.m.
Number of subjects: 6
Study 8398289 — intervention group
Group type: EXPERIMENTAL
Intervention: doxifluridine (dFUR) 4000 mg/m2 daily for 5 days every 28 days
Number of subjects: 222
Study 8398289 — intervention group
Group type: COMPARATOR
Intervention: fluorouracil (FU) 500 mg/m2 daily for 5 days every 28 days
Number of subjects: 222
Study 3299905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg single oral dose)
Number of subjects: 30
Study 3299905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (50 mg daily for two days and 100 mg twice daily for the following six days, total 1.3 g in eight days)
Number of subjects: 30
Study 3299905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3299905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30
Study 3299905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 30
Study 30187287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based protocol and tailored patient instruction materials
Number of subjects: 0
Study 30187287 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27905340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide (one drop preinjection)
Number of subjects: 352
Study 27905340 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab IVI (control group)
Number of subjects: 352
Study 24381054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin followed by CMF (4 cycles each)
Number of subjects: 705
Study 24381054 — intervention group
Group type: COMPARATOR
Intervention: CMF (6 cycles) alone
Number of subjects: 705
Study 24381054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 705
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) cultivar CDC Fibar
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) cultivar AC Parkhill
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) cultivar CDC Fibar
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) cultivar AC Parkhill
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta AC Parkhill
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta Celebrity
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) pasta
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta
Number of subjects: 30
Study 22833662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data from Expts. 1 and 2
Number of subjects: 30
Study 20458906 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS + GA
Number of subjects: 60
Study 20458906 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 60
Study 18279685 — intervention group
Group type: COMPARATOR
Intervention: 7-day hormone-free interval (HFI) with placebo
Number of subjects: 33
Study 18279685 — intervention group
Group type: EXPERIMENTAL
Intervention: 84/7-day cycle of 150 mcg LNG/30 mcg EE for 84 days followed by 7 days of 10 mcg EE
Number of subjects: 33
Study 18279685 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7-day cycle of 150 mcg LNG/30 mcg EE for 21 days followed by 7 days of placebo
Number of subjects: 33
Study 18279685 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day EE-supplemented interval after 84 days of an extended OC
Number of subjects: 33
Study 15731988 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) function assessment using the Tei index in fetuses with TVD
Number of subjects: 31
Study 14688542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinehart Reeves lens
Number of subjects: 60
Study 14688542 — intervention group
Group type: COMPARATOR
Intervention: Mountford BE lens
Number of subjects: 60
Study 14688542 — intervention group
Group type: COMPARATOR
Intervention: DreimLens
Number of subjects: 60
Study 14688542 — intervention group
Group type: COMPARATOR
Intervention: Contex D Series 4 lens
Number of subjects: 60
Study 14688542 — intervention group
Group type: EXPERIMENTAL
Intervention: All lens types
Number of subjects: 60
Study 10367614 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterdependency Scale (CDS) administered to patients with chronic pain
Number of subjects: 150
Study 8897388 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐7 (7% carbohydrate‐electrolyte solution)
Number of subjects: 8
Study 8897388 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐0/21 (placebo for first 90 min then a 21% glucose solution)
Number of subjects: 8
Study 8897388 — intervention group
Group type: COMPARATOR
Intervention: CON (artificially sweetened placebo)
Number of subjects: 8
Study 1825972 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily (n = 31)
Number of subjects: 64
Study 1825972 — intervention group
Group type: COMPARATOR
Intervention: 50 mg indomethacin 3-times daily (n = 33)
Number of subjects: 64
Study 6638001 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 0
Study 6638001 — intervention group
Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study 31888378 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (n = 302)
Number of subjects: 607
Study 31888378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 305)
Number of subjects: 607
Study 30985534 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 1228
Study 30985534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 28880047 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure messaging application (WhatsApp)
Number of subjects: 345
Study 28880047 — intervention group
Group type: COMPARATOR
Intervention: Telephone (standard communication)
Number of subjects: 345
Study 27023257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine
Number of subjects: 133
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual monoenergetic reconstructions at 60 keV
Number of subjects: 71
Study 24872006 — intervention group
Group type: COMPARATOR
Intervention: M‐0.3 series (linear blending setting emulating 120 kV acquisition)
Number of subjects: 71
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 keV series
Number of subjects: 71
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 keV series
Number of subjects: 71
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 keV
Number of subjects: 71
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 keV
Number of subjects: 71
Study 24872006 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐0.3 series
Number of subjects: 71
Study 22936795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 800
Study 22936795 — intervention group
Group type: COMPARATOR
Intervention: No dietary intervention (Control)
Number of subjects: 800
Study 19886982 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of isoniazid
Number of subjects: 324
Study 19886982 — intervention group
Group type: COMPARATOR
Intervention: Three times a week dosing of isoniazid
Number of subjects: 324
Study 19886982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing schedules (daily and three times a week)
Number of subjects: 324
Study 19886982 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from overcrowded homes
Number of subjects: 324
Study 19886982 — intervention group
Group type: EXPERIMENTAL
Intervention: Children older than 4 years
Number of subjects: 324
Study 17357792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (intermittent free weight squatting at 70% of 1‐RM)
Number of subjects: 10
Study 17357792 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (30 min of continuous cycling at 70% of VO(2max))
Number of subjects: 10
Study 17357792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 10
Study 17357792 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 10
Study 15297100 — intervention group
Group type: EXPERIMENTAL
Intervention: Roti
Number of subjects: 65
Study 15297100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread
Number of subjects: 65
Study 15297100 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice
Number of subjects: 65
Study 15297100 — intervention group
Group type: COMPARATOR
Intervention: Control (Non-diabetic subjects)
Number of subjects: 65
Study 11328332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 1522
Study 11328332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1522
Study 11328332 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 1522
Study 11328332 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1522
Study 9221683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (8 to 12 sessions at absolute atmosphere of 1.3‐1.6 for 40 min)
Number of subjects: 65
Study 9221683 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (125 mg daily)
Number of subjects: 65
Study 9221683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg daily)
Number of subjects: 65
Study 9221683 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygenation
Number of subjects: 65
Study 8424516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose at 10 g/h during the operation
Number of subjects: 20
Study 8424516 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose)
Number of subjects: 20
Study 3475193 — intervention group
Group type: COMPARATOR
Intervention: Manually operated ventilation bag (group C)
Number of subjects: 30
Study 3475193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume meter at the exhalation valve of the ventilation bag (group V)
Number of subjects: 30
Study 3475193 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable ventilator set to the minute volume (group O)
Number of subjects: 30
Study 29970638 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of Ocimum sanctum
Number of subjects: 40
Study 29970638 — intervention group
Group type: COMPARATOR
Intervention: Triple antibiotic paste (TAP)
Number of subjects: 40
Study 29970638 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 27480449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 154
Study 27480449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 24916176 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (IE)
Number of subjects: 28
Study 24916176 — intervention group
Group type: COMPARATOR
Intervention: Didactic educational intervention (DE)
Number of subjects: 28
Study 22926608 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 91
Study 22926608 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 91
Study 22926608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 20533106 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Number of subjects: 91
Study 20533106 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Number of subjects: 91
Study 18221441 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR) for 12 weeks
Number of subjects: 49
Study 18221441 — intervention group
Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 49
Study 16319343 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 523
Study 16319343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 12684649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg or 100 microg/kg, single SC injection on day 2 of chemotherapy cycle)
Number of subjects: 448
Study 12684649 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day, daily SC injections until ANC > or =10 x 10(9)/l or for up to 14 days)
Number of subjects: 448
Study 12684649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 448
Study 12684649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim and Filgrastim
Number of subjects: 448
Study 14740590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 40
Study 14740590 — intervention group
Group type: COMPARATOR
Intervention: TIVA by propofol (Group P)
Number of subjects: 40
Study 9708556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastructural assessment of dermal connective tissue components via transmission electron microscopy
Number of subjects: 25
Study 9708556 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of cervical artery dissections with connective tissue abnormalities
Number of subjects: 25
Study 9708556 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of structural abnormalities in the extracellular matrix
Number of subjects: 25
Study 8574437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, two inhalations) administered 30 minutes before exercise
Number of subjects: 30
Study 8574437 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 30
Study 1978025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold provocation in Raynaud's subjects
Number of subjects: 14
Study 1978025 — intervention group
Group type: COMPARATOR
Intervention: Cold provocation in control subjects
Number of subjects: 14
Study 1978025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital arterial pulsatility in Raynaud's subjects
Number of subjects: 14
Study 1978025 — intervention group
Group type: COMPARATOR
Intervention: Digital arterial pulsatility in control subjects
Number of subjects: 14
Study 155097 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 119
Study 155097 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 119
Study 30616380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus PUFAs (3600 mg/day for three courses, each course included 3 weeks)
Number of subjects: 34
Study 30616380 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus placebo
Number of subjects: 34
Study 28219692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg oral once daily for 45 days
Number of subjects: 472
Study 28219692 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux 2.5 mg subcutaneous once daily for 45 days
Number of subjects: 472
Study 28219692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 472
Study 28219692 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 472
Study 25222349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 1700000
Study 25222349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700000
Study 23604707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 30
Study 23604707 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (3 cycles of 5 min upper-arm cuff inflation to 20 mmHg)
Number of subjects: 30
Study 22136960 — intervention group
Group type: EXPERIMENTAL
Intervention: n3-LCPUFA (900 mg daily)
Number of subjects: 76
Study 22136960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 19210165 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 0
Study 19210165 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 0
Study 19210165 — intervention group
Group type: EXPERIMENTAL
Intervention: Isogenic pfcrt-modified parasite lines
Number of subjects: 0
Study 16626413 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of IBS-QOL
Number of subjects: 72
Study 16626413 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of WPAI:IBS
Number of subjects: 72
Study 16626413 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of EQ-5D
Number of subjects: 72
Study 16626413 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire for IBS-QOL
Number of subjects: 72
Study 16626413 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire for WPAI:IBS
Number of subjects: 72
Study 16626413 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire for EQ-5D
Number of subjects: 72
Study 16626413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease of use comparison between EDC and paper
Number of subjects: 72
Study 15599140 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (Xigris) 24 microg/kg/hr for 96 hrs
Number of subjects: 1690
Study 11257651 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA fluorescence endoscopy
Number of subjects: 102
Study 11257651 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy
Number of subjects: 102
Study 9454481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron prostheses
Number of subjects: 40
Study 9454481 — intervention group
Group type: COMPARATOR
Intervention: PTFE prostheses
Number of subjects: 40
Study 9454481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8217359 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 177
Study 8217359 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 177
Study 3304522 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheterization
Number of subjects: 66
Study 3304522 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheterization
Number of subjects: 66
Study 24933484 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach/right-hand contractions
Number of subjects: 75
Study 24933484 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal/left-hand contractions
Number of subjects: 75
Study 24933484 — intervention group
Group type: COMPARATOR
Intervention: Control/no contraction
Number of subjects: 75
Study 24102666 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 88
Study 24102666 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 88
Study 21318452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose omega 3 fatty acids (1 gram of fish oil capsule containing 300 mg of eicosapentaenoic acid and docosahexaenoic acid daily for 6 months
Number of subjects: 66
Study 21318452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19752672 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP program
Number of subjects: 66
Study 19752672 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 17766533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118
Study 17766533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 11292954 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF (2 tablets daily for 24 weeks)
Number of subjects: 140
Study 11292954 — intervention group
Group type: COMPARATOR
Intervention: Control (standard compressive therapy plus external treatment)
Number of subjects: 140
Study 11292954 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF (for ulcers <3 cm)
Number of subjects: 140
Study 11292954 — intervention group
Group type: COMPARATOR
Intervention: Control (for ulcers <3 cm)
Number of subjects: 140
Study 11292954 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF (for ulcers between 3 and 6 cm)
Number of subjects: 140
Study 11292954 — intervention group
Group type: COMPARATOR
Intervention: Control (for ulcers between 3 and 6 cm)
Number of subjects: 140
Study 11292954 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 140
Study 11292954 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study 9801287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropanol 70%
Number of subjects: 20
Study 9801287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropanol 80%
Number of subjects: 20
Study 9801287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropanol 90%
Number of subjects: 20
Study 9801287 — intervention group
Group type: COMPARATOR
Intervention: n-Propanol 60% (control)
Number of subjects: 20
Study 8033573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 22